ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aligos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.84−0.02 (-0.41%)
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
Aligos Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Market Cap | $60.45M | $166.30M |
| Enterprise Value | $30.07M | $88.19M |
| PS Ratio | 16.16 | 3.65 |
| PB Ratio | 1.90 | 2.03 |
| P/TBV Ratio | 1.90 | 2.29 |
Enterprise value
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 8.04 | 2.51 |
Income (trailing twelve months)
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Revenue | $3.74M | $58.34M |
| Operating Income | -$78.99M | -$21.40M |
| Pretax Income | -$72.75M | -$14.34M |
| Net Income | -$75.96M | -$22.46M |
| EBITDA | -$78.99M | -$16.91M |
Margins
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -2112.1% | -44.0% |
| Pretax Margin | -1945.1% | -13.3% |
| Profit Margin | -2031.1% | -40.2% |
| EBITDA Margin | -2112.1% | -30.2% |
Returns
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -113.6% | -53.2% |
| Return on Assets (ROA) | -75.6% | -40.9% |
| Return on Capital Employed (ROCE) | -208.0% | -38.1% |
Growth
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 19.4% | 5.96% |
Balance sheet
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $30.38M | $61.43M |
| Net Cash (Debt) | $30.38M | $15.35M |
| Net Cash Per Share | $2.43 | $0.66 |
| Equity (Book Value) | $31.88M | $49.09M |
| Book Value Per Share | $2.55 | $1.37 |
| Tangible Book Value | $31.88M | $23.52M |
| Working Capital | $33.78M | $76.81M |
Financial position
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 2.19 | 3.34 |
| Quick Ratio | 2.05 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$94.17M | -$12.35M |
Efficiency
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.04 | 0.39 |
| Revenue Per Employee | $45.61K | $404.87K |
| Profits Per Employee | -$926.37K | -$703.34K |
| Employee Count | 82 | 74 |
Dividends and yields
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -125.7% | -23.3% |
Shares
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 12,489,100 | 58,127,000 |
| Shares Change (YoY) | 31.6% | 10.9% |
| Shares Change (QoQ) | 0.79% | 0.54% |
| Shares Held by Institutions | 18.4% | 59.4% |
Taxes
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Income Tax | $3.21M | $79.87K |
Scores
| Measure | Aligos Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -16.28 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Aligos Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.